Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
FDA cancels Cipla pharma's CFA drug sale licence in Pune
The Maharashtra Food and Drug Administration (FDA) cancelled the carry and forwarding agent (CFA) drug sale licence of Cipla Pharma & Life Sciences Ltd, Vadki, Pune. During an inspection conducted in June this year, FDA officials found…
FDA cancels drug sale licences of Cipla Pharma & Life Sciences' Pune Carry and Forwarding unit
The Maharashtra Food and Drug Administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) unit in Pune over serious irregularities related to the packaging, storage and recall of Reactin Plus…
Maharashtra FDA crackdown on Cipla Pharma's Pune unit, cancels licence over 'unauthorised promotional text' on Reactin Plus
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) facility at Wadki in Pune, citing serious irregularities found during inspections linked to…
Why won't the legacy media cover Big Pharma properly anymore?
“It is difficult to get a man to understand something when his salary depends on his not understanding it.” The muckraking journalist Upton Sinclair wrote those words in 1934. Truer words have never been spoken; I made them the…
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 6% - Here's What Happened
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price rose 6% during trading on Friday. The company traded as high as $17.92 and last traded at $17.92. Approximately 302 shares were traded during…
Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN
Jefferies Financial Group Inc. acquired a new position in Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired…
Coastal Bridge Advisors LLC Invests $1.36 Million in Urogen Pharma $URGN
Coastal Bridge Advisors LLC bought a new stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 37,000 shares of the…
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by HC Wainwright to Strong-Buy Rating
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by investment analysts at HC Wainwright to a 'strong-buy' rating in a research note issued to investors on Thursday, Zacks.com reports. Can BioMarin Stock Live Up to Wall Street's…
Palo Alto Investors LP Purchases New Shares in Urogen Pharma $URGN
Palo Alto Investors LP bought a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 24,500 shares of the company's…
Stonepine Capital Management LLC Makes New Investment in Nuvectis Pharma, Inc. $NVCT
Stonepine Capital Management LLC bought a new stake in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 40,000 shares of the…
Harvey Capital Management Inc. Takes $10.34 Million Position in BridgeBio Pharma, Inc. $BBIO
Harvey Capital Management Inc. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional…
KAIST unveils homegrown AI model for predicting protein structures, drug binding
Researchers at the Korea Advanced Institute of Science and Technology (KAIST) said Friday they have developed a biomolecular artificial intelligence (AI) model, called K-Fold, that predicts protein structures and how drug candidates bind to them…
BioNTech, Roche Scrap Cancer Vaccine Trial in Blow to New Field
BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, dashing hopes that had been raised by a rival drugmaker's recent success in the same field. The German biotech and its Swiss pharma partner took the decision after…
BioCryst is profitable. Now it wants to buy more rare disease drugs
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to…
Opinion | You're Living Longer, Americans
Pessimists on the political left and right can't find much good to say about America these days, so allow us to help. American life expectancy hit a record in 2024 as deaths fell from most major causes, according to a Centers for Disease Control…
Receive a Daily briefing on Pharma Industry News
Get Started